Peer-reviewed veterinary case report
Blood levels of CCL2 and CXCL12 in female dogs with mammary tumors
By Szczubiał, M et al.·Published in Polish journal of veterinary sciences·2023·Department and Clinic of Animal Reproduction·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Plasma levels of chemokines CCL2 and CXCL12 in female dogs with malignant mammary gland tumours without and with metastases.
- Species:
- dog
Plain-English summary
A group of female dogs with malignant mammary gland tumors were tested for two specific proteins, CCL2 and CXCL12, to see if their levels were different in dogs with and without metastases (spread of cancer). The study found that dogs with metastases had higher levels of these proteins compared to healthy dogs, suggesting a link between these proteins and cancer spread. While the levels were also higher in dogs with more advanced tumors, the differences weren't significant enough to draw firm conclusions. More research is needed to understand the role of these proteins in cancer progression.
People also search for: dog mammary tumor symptoms · female dog cancer treatment · high CCL2 levels in dogs
Abstract
The aim of this study was to evaluate the plasma levels of chemokines CCL2 and CXCL12 in female dogs with malignant mammary gland tumours without and with metastases. The concentrations of CCL2 and CXCL12 were determined in 25 female dogs with malignant mammary gland tumours (15 without metastases and 10 with metastases) and 10 healthy control animals using a specific canine ELISA assay. The mean plasma concentrations of CCL2 and CXCL12 were significantly higher (p<0.05) in the metastatic group compared to the control group. Moreover, the concentrations of these chemokines were markedly higher in the dogs with metastases than in those without metastases; however, a statistically significant difference was not found. The concentrations of both tested chemokines were numerically increased in the dogs with grade 2 and grade 3 carcinomas compared to the dogs with grade 1 carcinomas but the differences did not reach statistical significance. In conclusion, the results of our study demonstrate that plasma concentrations of chemokines CCL2 and CXCL12 are significantly increased in the dogs with metastatic malignant mammary gland tumours compared to the healthy dogs and show an upward trend compared to those without metastases. However, clarifying whether the increase of these chemokines is a cause or an effect of metastasis in female dogs with malignant mammary gland tumours as well as their potential role in metastatic process requires further research.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37727066/